Hetero-Multivalency of Pseudomonas Aeruginosa Lectin LecA Binding to Model Membranes
Authors
Affiliations
A single glycan-lectin interaction is often weak and semi-specific. Multiple binding domains in a single lectin can bind with multiple glycan molecules simultaneously, making it difficult for the classic "lock-and-key" model to explain these interactions. We demonstrated that hetero-multivalency, a homo-oligomeric protein simultaneously binding to at least two types of ligands, influences LecA (a Pseudomonas aeruginosa adhesin)-glycolipid recognition. We also observed enhanced binding between P. aeruginosa and mixed glycolipid liposomes. Interestingly, strong ligands could activate weaker binding ligands leading to higher LecA binding capacity. This hetero-multivalency is probably mediated via a simple mechanism, Reduction of Dimensionality (RD). To understand the influence of RD, we also modeled LecA's two-step binding process with membranes using a kinetic Monte Carlo simulation. The simulation identified the frequency of low-affinity ligand encounters with bound LecA and the bound LecA's retention of the low-affinity ligand as essential parameters for triggering hetero-multivalent binding, agreeing with experimental observations. The hetero-multivalency can alter lectin binding properties, including avidities, capacities, and kinetics, and therefore, it likely occurs in various multivalent binding systems. Using hetero-multivalency concept, we also offered a new strategy to design high-affinity drug carriers for targeted drug delivery.
Lectin-Based Substrate Detection in Fabry Disease Using the Gb3-Binding Lectins StxB and LecA.
Elcin-Guinot S, Lagies S, Avi-Guy Y, Neugebauer D, Huber T, Schell C Int J Mol Sci. 2025; 26(5).
PMID: 40076891 PMC: 11900420. DOI: 10.3390/ijms26052272.
Sugar-Coated: Can Multivalent Glycoconjugates Improve upon Nature's Design?.
Leslie K, Berry S, Miller G, Mahon C J Am Chem Soc. 2024; 146(40):27215-27232.
PMID: 39340450 PMC: 11467903. DOI: 10.1021/jacs.4c08818.
Hu Q, Wu H ACS Meas Sci Au. 2024; 4(3):307-314.
PMID: 38910864 PMC: 11191725. DOI: 10.1021/acsmeasuresciau.4c00014.
Revisiting the immunopathology of congenital disorders of glycosylation: an updated review.
Pascoal C, Francisco R, Mexia P, Pereira B, Granjo P, Coelho H Front Immunol. 2024; 15:1350101.
PMID: 38550576 PMC: 10972870. DOI: 10.3389/fimmu.2024.1350101.
Advanced drug delivery and therapeutic strategies for tuberculosis treatment.
Nair A, Greeny A, Nandan A, Sah R, Jose A, Dyawanapelly S J Nanobiotechnology. 2023; 21(1):414.
PMID: 37946240 PMC: 10634178. DOI: 10.1186/s12951-023-02156-y.